A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes

Type 2 Diabetes Clinical Trial

Official title:

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment With DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo in Subjects With Type 2 Diabetes Mellitus (Protocol No. DIO-502)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00494663
• Other study ID #: DIO-502
• Status: Terminated
• Phase: Phase 2
• First received: June 28, 2007
• Last updated: November 11, 2008
• Start date: July 2007
• Est. completion date: December 2008

Study information

• Verified date: November 2008
• Source: DiObex
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationAustralia: Therapeutic Goods AdministrationNew Zealand: Medsafe
• Study type: Interventional

Clinical Trial Summary

DiObex Inc. is developing an experimental drug (DIO-902) that is made up of part of the ketoconazole molecule for the treatment of elevated blood glucose associated with type 2 diabetes mellitus. Ketoconazole (Nizoral®) is a drug available by prescription for the treatment of fungal infections however DIO-902 is an investigational drug. DIO-902 may lower blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated cortisol may contribute to the development of type 2 diabetes.

The purpose of this research study is to test the safety of DIO-902 when taken by mouth with metformin and the cholesterol-lowering drug atorvastatin to determine the type and severity of any side effects from this treatment.

Other purposes of the study are to see how the treatment affects your blood glucose levels, cholesterol levels, blood pressure, and waist circumference.

Description:

DIO-902 may lower blood glucose by lowering levels of a naturally occurring hormone called cortisol. Elevated cortisol may contribute to the development of type 2 diabetes. Clinical trials with ketoconazole have been carried out in patients with type 2 diabetes. Three clinical trials with DIO-902 have been completed in which 37 patients with type 2 diabetes and 42 normal healthy volunteers (people without type 2 diabetes) were enrolled. Patients in these studies received multiple doses of DIO-902. DIO-902 may reduce the level of cortisol in your blood and therefore may provide you with better control of your blood glucose levels.

STUDY DRUG ASSIGNMENT

You will be randomized, that is, given a 1 in 4 chance of receiving either 150mg/day of DIO-902, 300mg/day of DIO-902, 450mg/day of DIO-902 or DIO-902 placebo and a 1 in 2 chance of receiving 10mg/day of atorvastatin or atorvastatin placebo. The study drug is a tablet and will be taken by mouth with water. You will take 3 tablets of DIO-902 or DIO-902 placebo and 1 tablet of atorvastatin or atorvastatin placebo each day. The tablets will be taken at the same time each day (2200h or 10:00pm). Neither you nor your doctor will know which dose of DIO-902 or DIO-902 placebo you are on or whether you are taking the atorvastatin or atorvastatin placebo. If necessary, your doctor has a way of finding out which dose you were assigned.

Atorvastatin

If you are taking any cholesterol-lowering drugs, these drugs must be discontinued on the day prior to the Pre-Treatment Visit (Week -4) and for the duration of the study. At Visit 1 (Week 0) you will be assigned to DIO-902 or DIO-902 placebo and to either atorvastatin or atorvastatin placebo. You will continue to take the assigned drug until Study Visit 4 (Week 8). At Study Visit 4 (Week 8) all patients will begin taking atorvastatin through the remainder of the study. Your DIO-902 or DIO-902 placebo assignment will remain the same. Atorvastatin tablets will be supplied to you until Study Visit 6 (Week 16). At this visit you will be given a prescription for a 28 day supply of atorvastatin 10mg.day to last until Study Visit 7 (Week 20).

There will a total of 9 study visits. At each visit all or some of the following will occur:

blood and urine samples will be taken, physical exam, assessment of side effects, and ECG will be performed.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 200
• Est. completion date: December 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

A subject may be included in this study if he/she meets all of the following criteria:

1. Male or female, age 18 to 75

2. Females of childbearing potential (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use the following acceptable birth control methods beginning at the Screening Visit and throughout the study:

1. abstinence

2. surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum

3. IUD in place for at least 3 months

4. barrier methods (condom or diaphragm) with spermicide

5. surgical sterilization of the partner (vasectomy for 6 months)

6. hormonal contraceptives for at least 3 months prior to the first dose

3. Diagnosis of type 2 diabetes mellitus (DM) for at least 6 months.

4. Type 2 diabetes may be treated only with metformin (metformin hydrochloride tablets or metformin hydrochloride extended-release tablets) at a total daily dose of 500 mg to the maximum labeled dose. (See Appendix G for List of Drug Trade Names).The dose of metformin must be stable for >8 weeks prior to the Pre-Treatment Visit (Week -4) and throughout the course of the study. The subject must not be on any other pharmacologic or over-the-counter treatments for diabetes.

5. HbA1C level of 7.0 to 10.0%

6. Fasting C-peptide level of >0.33 nmol/l (1.0 ng/ml)

7. ACTH stimulation test results with any cortisol level of >18 µg/dl at baseline or 60 minutes

8. Normal complete blood count (CBC) with platelets and differential

9. 12-lead electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality. Subjects with QTc interval of >450 msec will be excluded from the study.

10. BMI of 27 to 42 kg/m2 (see Appendix B)

11. Subjects with a history of hypertension may be on a stable anti-hypertensive regimen for (except those drugs stated under Exclusion Criterion 8) for >6 weeks prior to the Pre-Treatment Visit (Week -4))

12. Ability to comprehend and a willingness to provide informed consent

Exclusion Criteria:

• A subject may be excluded from this study if he/she meets any of the following criteria:

1. Previous participation in a clinical trial with DIO-902.

2. History of any atherosclerotic disorder (myocardial infarction, unstable angina, cerebrovascular accident, peripheral vascular disease or congestive heart failure secondary to ischemic myocardial injury) that would, in the estimation of the Investigator, make it unsafe to stop all lipid lowering drugs for up to 12 weeks during the course of the study.

3. Known hypersensitivity or idiosyncratic reaction related to ketoconazole or other imidazole compounds.

4. History of malignancy (except basal cell carcinoma) within the 3 years before the initial dose of the study medication.

5. Excessive alcohol intake (>20 g per day for females (1.5 standard alcohol drinks) or >30 g per day for males (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) or drug abuse. (1.0 fluid oz (US) = 29.57 ml)

6. Any other clinically significant medical condition, as determined by the Investigator. These clinically significant medical conditions include, but are not limited to, uncontrolled hypertension, NYHA class III or IV CHF, proliferative diabetic retinopathy and neuropathic symptoms that limit activities of daily living.

7. Participation in another clinical trial and/or treatment received with any investigational agent within one month before the initial dose of study medication.

8. Concomitant therapy with the following: (See Appendix G for List of Drug Trade Names)

1. weight loss medications

2. oral or injected hypoglycemics (metformin is allowed) or insulin

3. oral, parenteral or inhaled steroids; nasal, topical ocular, intravitreal, and low to moderate potency topical steroids are allowed

4. dihydropyridine calcium channel blockers (amlodipine, diltiazem and verapamil are allowed)

5. H2 antagonists and proton pump inhibitors (liquid and tablet antacids are allowed)

6. midazolam, triazolam, alprazolam, terfenadine, astemizole, digoxin, coumarin derivatives, phenytoin, rifampin, HIV protease inhibitors, spironolactone, aliskiren, erythromycin or clarithromycin, cyclosporine or tacrolimus

7. Subjects currently taking lipid lowering medications may be enrolled if the Investigator determines that the subject does not have any conditions that preclude cessation of lipid lowering treatment for up to 12 weeks. [All subjects will be required to discontinue all lipid lowering therapies during the 4 week Pre-Treatment Period and will then be randomized to receive either atorvastatin 10 mg or atorvastatin placebo during the first 8 weeks of the Treatment Period. All subjects will then receive atorvastatin 10 mg during weeks 8 to 16 of the Treatment Period.] Subjects may not be on any other lipid lowering agent through Visit 7 (Week 20) of the study.

9. History of HIV

10. Positive hepatitis B (HbsAg) or positive hepatitis C (Hepatitis C antibody) test during Screening

11. Liver function tests must not be above the following cut-offs: ALT and/or AST >3.0X ULN, AP >1.5X ULN and total bilirubin >ULN. (If all LFTs are WNL and total bilirubin is elevated, a retest of direct and indirect bilirubin may be performed. Subjects with indirect total bilirubin up to 3X ULN (presumed Gilbert's syndrome) may be enrolled if all other LFTs are WNL.)

12. CK must not be >2.5X ULN if not clearly related to recent exercise, injury or unusual activity

13. Creatinine must not be >1.4 mg/dl in females and >1.5 mg/dl in males.

14. Thyroid stimulating hormone level >1.5X ULN

15. History of lactic acidosis

16. Known hypersensitivity to cosyntropin (ACTH) or any component of the formulation (mannitol or sodium chloride)

17. Known intolerance to statin drugs

18. Any other condition which increases the risk of participation in the trial in the opinion of the investigator

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Type 2 Diabetes

Intervention

Drug:
• DIO-902
150mg tablet once per day for 16 weeks
• DIO-902
300mg tablet once per day for 16 weeks
• DIO-902
450mg DIO-902 tablet once daily for 16 weeks
• DIO-902 placebo
DIO-902 placebo tablet once daily for 16 weeks
• DIO-902
150mg tablet of DIO-902 once daily for 16 weeks
• DIO-902
300mg DIO-902 tablet daily for 16 weeks
• DIO-902
450mg DIO-902 tablet for 16 weeks
• DIO-902 placebo
DIO-902 placebo tablet once daily for 16 weeks

Locations

Country	Name	City	State
Australia	Flinders Medical Centre	Adelaide	South Australia
Australia	ECRU	Box Hill, Melbourne	Victoria
Australia	School of Medicine and Pharmacology	Fremantle	Western Australia
Australia	Endocrinology Research Unit	Herston Road
Australia	Keough Institute	Nedands	Western Australia
Australia	Lyell McEwin Hospital	North Western Adelaide	South Australia
Australia	Endocrinology Department	St Leonards
Australia	Royal Melbourn Hospital	Victoria
New Zealand	Lipid and Diabetes Research	Christchurch
New Zealand	Waikaito Hospital	Hamilton
New Zealand	Middlemore Hospital	Otahuhu	Auckland
New Zealand	Diabetes Centre	Wellington
United States	Covance CRU	Austin	Texas
United States	Diabetes Research Goup University of Hawaii at Manoa	Honolulu	Hawaii
United States	Research Solutions	Jonesboro	Arkansas
United States	Advanced Medical Research	Lakewood	California
United States	Arkansas Primary Care Clinic	Little Rock	Arkansas
United States	Dr. Terence Hart	Muscle Shoals	Alabama
United States	Creighton Diabetes Center	Omaha	Nebraska
United States	Covance Clinical Research Unit - Dr. Andrew Ahmann	Portland	Oregon
United States	Diabetes Glandular and Disease Research Associates	San Antonio	Texas
United States	Mills-Peninsula Helath Services	San Mateo	California
United States	Genova Research	Tucson	Arizona
United States	AHS Oklahoma Physician Group	Tulsa	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
DiObex

Countries where clinical trial is conducted

United States,  Australia,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1. The primary efficacy endpoint will be change from baseline to the end of treatment (Study Visit 6, Week 16) in HbA1c		16 weeks	No
Secondary	1. Change from baseline to Week 8 in total and LDL-cholesterol (LDL-C) 2. Change from baseline to the end of treatment (Week 16) in the following : Seated blood pressure (systolic, diastolic and mean arterial pressure) Fasting blood glucose		16 weeks	No